Pluronic F127-based systemic vaccine delivery systems (Q33203706)

23 July 2017

Pluronic F127-based systemic vaccine delivery systems (English)

1 reference

23 July 2017

0 references

Claire M Coeshott

1

1 reference

23 July 2017

S Louise Smithson

2

1 reference

23 July 2017

Evie Verderber

3

1 reference

23 July 2017

Adrian Samaniego

4

1 reference

23 July 2017

Joan M Blonder

5

1 reference

23 July 2017

Gary J Rosenthal

6

1 reference

23 July 2017

M A Julie Westerink

7

1 reference

23 July 2017

language of work or name

English

0 references

publication date

1 June 2004

1 reference

23 July 2017

1 reference

23 July 2017

22

1 reference

23 July 2017

19

1 reference

23 July 2017

2396-2405

1 reference

ProJuvant (Pluronic F127/chitosan) enhances the immune response to intranasally administered tetanus toxoid

23 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.064

Drug delivery matrix containing native protein precipitates suspended in a poloxamer gel

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.064

Carbohydrate biopolymers enhance antibody responses to mucosally delivered vaccine antigens

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.064

Stimulation of mucosal and systemic antibody responses against Bordetella pertussis filamentous haemagglutinin and recombinant pertussis toxin after nasal administration with chitosan in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.064

A mucosal vaccine against diphtheria: formulation of cross reacting material (CRM(197)) of diphtheria toxin with chitosan enhances local and systemic antibody and Th2 responses following nasal delivery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.064

Immune stimulating activity of two new chitosan containing adjuvant formulations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.064

CpG oligodeoxynucleotides act as adjuvants for pneumococcal polysaccharide-protein conjugate vaccines and enhance antipolysaccharide immunoglobulin G2a (IgG2a) and IgG3 antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.064

CpG DNA as a Th1-promoting adjuvant in immunization against Trypanosoma cruzi

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.064

Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.064

Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.064

Immunization of mice with DNA encoding fragment C of tetanus toxin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.064

B cell memory and the long-lived plasma cell

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.064

Long-lived plasma cells: a mechanism for maintaining persistent antibody production.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.064

Humoral immunity due to long-lived plasma cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.064

CpG DNA induces stronger immune responses with less toxicity than other adjuvants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.064

Oral, intrarectal and intranasal immunizations using CpG and non-CpG oligodeoxynucleotides as adjuvants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.064

The potential of oligodeoxynucleotides as mucosal and parenteral adjuvants.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.064

Synthetic oligodeoxynucleotides containing CpG motifs enhance immunogenicity of a peptide malaria vaccine in Aotus monkeys.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.064

CpG-containing oligodeoxynucleotides, in combination with conventional adjuvants, enhance the magnitude and change the bias of the immune responses to a herpesvirus glycoprotein.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.064

The polyoxyethylene/polyoxypropylene block co-polymer poloxamer-407 selectively redirects intravenously injected microspheres to sinusoidal endothelial cells of rabbit bone marrow

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.064

Long-term protection of mice against Leishmania major with a synthetic peptide vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.064

A combination of poloxamers increases gene expression of plasmid DNA in skeletal muscle

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.064

Improvement of receptor-mediated gene delivery to HepG2 cells using an amphiphilic gelling agent

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.064

Delivery of Flt3 ligand (Flt3L) using a poloxamer-based formulation increases biological activity in mice.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.064

Factors affecting short-term and long-term stabilities of proteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.064

Field Evaluation of a Human Anthrax Vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.064

Delayed life-threatening reaction to anthrax vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.064

Sustained delivery of interleukin-2 from a poloxamer 407 gel matrix following intraperitoneal injection in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.064

Percutaneous absorption of indomethacin from pluronic F127 gels in rats

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.064

Use of poloxamer polymers to stabilize recombinant human growth hormone against various processing stresses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.064

Evaluation of pluronic F127-based sustained-release ocular delivery systems for pilocarpine using the albino rabbit eye model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.064

In vitro evaluation of pluronic F127-based controlled-release ocular delivery systems for pilocarpine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.064

Controlled release of lidocaine from injectable gels and efficacy in rat sciatic nerve block.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.064

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.064

The adjuvant activity of nonionic block polymer surfactants. III. Characterization of selected biologically active surfaces

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.064

10.1016/J.VACCINE.2003.11.064

7 January 2021

Identifiers

DOI

1 reference

23 July 2017

1 reference